

C L A I M S

1. Use of a WNT5A peptide or derivatives thereof in the manufacture of a medicament for the treatment of colon cancer, colorectal cancer or breast cancer in a subject in need thereof, wherein the WNT5A peptide comprising comprises X_ADGX_BEL (SEQ. ID. NO. 2), or a formylated derivative thereof, wherein the derivative X_A is methionine (M) or norleucine, X_B is cysteine (C) or alanine (A), or a formylated derivative thereof, wherein the total length of the peptide is equal to or less than 2050 amino acids, wherein
 said medicament is to be administered with one or more checkpoint inhibitors either simultaneously or sequentially, wherein said subject is defined as being responsive to immune checkpoint inhibitors and wherein the subject in need thereof has an upregulated tumour expression of one or more immune checkpoint molecule selected from the group consisting of CTLA-4, PD-L1 and/or CD47.

2. Use of a WNT5A peptide or derivatives thereof in combination with one or more checkpoint inhibitors in the manufacture of a medicament for the treatment of colon cancer, colorectal cancer or breast cancer in a subject in need thereof, wherein the WNT5A peptide comprising comprises X_ADGX_BEL (SEQ. ID. NO. 2), or a formylated derivative thereof, wherein the derivative X_A is methionine (M) or norleucine, X_B is cysteine (C) or alanine (A), or a formylated derivative thereof, wherein the total length of the peptide is equal to or less than 50-20 amino acids.

~~3. The use according to claim 1 or claim 2, wherein said subject is defined as being responsive to immune checkpoint inhibitors.~~

4.3. The use according to any one of the preceding claims, wherein the at least one checkpoint inhibitor is an inhibitor of an immune checkpoint molecule selected from the group consisting of CTLA-4, PD-1, PD-L1 and CD47.

5.4. The use according to any one of the preceding claims, wherein

the checkpoint inhibitor is an anti-CTLA4-antibody, anti-PD-1-antibody, anti-PD-L1-antibody and/or anti-CD47-antibody.

6.5. The use according to claim 54, wherein the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

7.6. The use according to claim 54, wherein the anti-PD-L1-antibody ~~an antibody~~ is atezolizumab, avelumab, durvalumab or pembrolizumab.

8.7. The use according to any one of the preceding claims, wherein the dosage of checkpoint inhibitor used is reduced as compared to the dosage used when not administering WNT5A simultaneously or sequentially.

~~9. The use according to any one of the preceding claims, wherein the subject in need thereof has an upregulated tumour expression of one or more immune checkpoint molecule selected from the group consisting of CTLA-4, PD-L1 and/or CD47.~~

10.8. The use according to any one of the preceding claims, wherein the checkpoint inhibitor is an anti-PD-L1-antibody and/or an anti-CTLA4-antibody and wherein the subject in need thereof has an upregulated tumour expression of CTLA-4, PD-L1 and/or CD47.

11.9. The use according to any one of the preceding claims, wherein the WNT5A peptide is selected from the group consisting of:

MDGCEL (SEQ. ID. NO. 3),
 GMDGCEL (SEQ. ID. NO. 4),
 EGMDGCEL (SEQ. ID. NO. 5),
 SEGMDGCEL (SEQ. ID. NO. 6),
 TSEGMDGCEL (SEQ. ID. NO. 7),
 KTSEGMDGCEL (SEQ. ID. NO. 8),
 NKTSEGMDGCEL (SEQ. ID. NO. 9),
 CNKTSEGMDGCEL (SEQ. ID. NO. 10),

LCNKTSEGMDGCEL (SEQ. ID. NO. 11),
 RLCNKTSEGMDGCEL (SEQ. ID. NO. 12),
 GRLCNKTSEGMDGCEL (SEQ. ID. NO. 13),
 QGRLCNKTSEGMDGCEL (SEQ. ID. NO. 14),
 TQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 15),
 GTQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 16), and
 LGTQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 17).

~~12.10.~~ The use according to any ~~one~~ of the preceding claims,
 wherein

the WNT5A peptide is hexapeptide MDGCEL (SEQ. ID. NO. 3).

~~13. Use of a WNT5A peptide or derivatives thereof in the manufacture of a medicament for the treatment of colon cancer, colorectal cancer or breast cancer in a subject, said subject being defined as responsive to immune checkpoint inhibitors and said subject having an upregulated tumour expression of one or more immune checkpoint molecule selected from the group consisting of CTLA-4, PD-L1 and/or CD47, the WNT5A peptide comprising $X_A D G X_B E L$ (SEQ. ID. NO. 2), or a formylated derivative thereof, wherein X_A is methionine (M) or norleucine, X_B is cysteine (C) or alanine (A), wherein the total length of the peptide is equal to or less than 50 amino acids.~~

~~14. The use according to claim 12, wherein the WNT5A peptide is selected from the group consisting of:~~

~~MDGCEL (SEQ. ID. NO. 3),
 GMDGCEL (SEQ. ID. NO. 4),
 EGMDGCEL (SEQ. ID. NO. 5),
 SEGMDGCEL (SEQ. ID. NO. 6),
 TSEGMDGCEL (SEQ. ID. NO. 7),
 KTSEGMDGCEL (SEQ. ID. NO. 8),
 NKTSEGMDGCEL (SEQ. ID. NO. 9),
 CNKTSEGMDGCEL (SEQ. ID. NO. 10),
 LCNKTSEGMDGCEL (SEQ. ID. NO. 11),~~

~~RLCNKTSEGMDGCEL (SEQ. ID. NO. 12),~~

~~GRLCNKTSEGMDGCEL (SEQ. ID. NO. 13),~~

~~QGRLCNKTSEGMDGCEL (SEQ. ID. NO. 14),~~

~~TQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 15),~~

~~GTQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 16), and~~

~~LGTQGRLCNKTSEGMDGCEL (SEQ. ID. NO. 17)~~